Answers are grounded in this paper and cite their sources.
Whole-genome and transcriptome sequencing can be leveraged for personalised cancer medicine. However, the resolution of malignant subclones within the tumour, a driver of therapeutic resistance, from bulk sequencing profiles relies on computational inference and generally requires high sequencing depth. Here, we applied single-cell multiomic sequencing to 25 tumour samples from 17 patients enrolled in the BC Cancer Personalised OncoGenomics programme to assess the extent to which single-cell profiling might enhance treatment planning for patients with advanced cancers. Across the cohort, we were able to resolve previously undetected subclonal mutations and immune cell populations associated with therapeutic efficacy. Additionally, in longitudinal cases, single-cell analyses tracked potential resistance mechanisms across biopsies. Furthermore, treatment-associated genes were heterogeneously distributed across malignant clusters, suggesting the need for combinatorial regimens. Some genes predicted to be targetable by bulk RNA-seq were also found to be predominantly expressed by normal populations. These findings demonstrate how the integration of single-cell data into translational research could enhance insights for precision cancer medicine.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: